E. García-Rey

Results of ARI‐0001 CART19 cell therapy in patients with relapsed/refractory CD19‐positive acute lymphoblastic leukemia with isolated extramedullary disease

E. Giné, S. Rives, J. Esteve, 2022, American journal of hematology.

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies.

E. Giné, S. Rives, J. Esteve, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Syngeneic hematopoietic stem cell transplantation after mobilization failure in an adolescent with intracranial germ cell tumor

O. Cruz, L. Martorell, M. Rovira, 2023, Pediatric blood & cancer.

Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry

R. Martino, M. Lozano, J. Cid, 2022, Bone Marrow Transplantation.

Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation

O. Valero, M. Lozano, J. Cid, 2022, Bone Marrow Transplantation.

Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?

R. Martino, C. Azqueta, S. Querol, 2021, Bone Marrow Transplantation.

Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

E. Giné, S. Rives, J. Esteve, 2021, Journal for ImmunoTherapy of Cancer.

Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

E. Giné, S. Rives, J. Esteve, 2021, Journal for ImmunoTherapy of Cancer.